MarketFriction

Zydus Lifesciences Ltd

NSE ZYDUSLIFE · BSE 532321 · Pharmaceuticals
₹1,145.70 -1.40%
NSE close2026-10-01
52 week range835.50 - 1,232.10
Market cap₹1,19,750 Cr.
P/E24.6
Nifty Next 50Nifty 100Nifty 200Nifty 500Nifty PharmaNifty Healthcare Index No price band Delivery 58.5%

Price

Drag to pan, scroll or pinch to zoom. Ruler (or Shift + drag) measures a move.Dashed lines: 52 week high and low. Prices adjusted for splits and bonuses.

Financials

Consolidated, Rs crore
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales4,3694,5055,5346,2085,2375,2696,5286,5746,1236,8647,5878,017
Expenses3,2233,4033,9034,1243,7763,8824,4024,4854,1075,0485,0336,088
Operating Profit1,1461,1021,6302,0841,4611,3882,1262,0882,0161,8162,5541,929
OPM %26%24%29%34%28%26%33%32%33%26%34%24%
Other Income5360160636857-1391557526-26388
Interest920353225327785101130123156
Depreciation184195205215234229238238302360508555
Profit before tax1,0069471,5501,9001,2711,1841,6721,9211,6871,3531,6601,307
Tax %22%23%21%23%29%15%25%23%27%29%19%27%
Net Profit8037901,2461,4829201,0261,2441,5211,2391,0231,341990
EPS in Rs7.917.8011.7514.119.0610.1711.6414.5812.5110.3612.659.42
Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales9,4279,37611,90513,16614,25315,10215,26517,23719,54723,24227,14828,592
Expenses7,0957,4749,07410,17411,45511,75811,92313,37814,16316,18318,67320,276
Operating Profit2,3321,9022,8312,9912,7983,3443,3423,8605,3847,0588,4758,316
OPM %25%20%24%23%20%22%22%22%28%30%31%29%
Other Income112127111183-264-1712,581-42229350-7-74
Interest53459119434216412713081166439510
Depreciation2923735395996967257137237649161,4081,725
Profit before tax2,0991,6122,3122,3821,4952,2855,0842,5854,8326,0276,6216,007
Tax %8%8%24%22%21%6%10%23%20%23%24%
Net Profit1,9641,5171,8101,8991,2042,1854,6182,0923,9734,6735,1244,593
EPS in Rs18.8914.5317.3518.0611.4920.8443.8319.3738.3644.9750.0944.94
Dividend Payout %17%22%20%19%30%17%6%31%8%24%2%
10 Years5 Years3 YearsTTM1 YearLast Year
Compounded Sales Growth11%12%16%21%
Compounded Profit Growth11%19%32%5%
Stock Price CAGR12%17%25%22%
Return on Equity20%21%21%21%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital102102102102102102102102101101101101
Reserves4,1495,5976,8588,64210,28410,27312,89016,89717,41519,72923,85227,011
Borrowings2,6512,4425,2075,4077,8997,9864,5844,2211,1958043,21312,496
Other Liabilities2,1442,2082,9373,6324,9455,1156,1896,4216,8518,2019,52311,065
Total Liabilities9,04710,35015,10417,78323,23123,47723,76527,64225,56228,83436,68950,673
Fixed Assets3,3523,7485,7556,48312,16412,23012,13312,25311,52112,36813,13424,106
CWIP7989511,5431,5278377427836611,2012,4232,6923,698
Investments1544164357466747658303,2881,5471,2206,4127,540
Other Assets4,7435,2357,3719,0289,5569,74010,01911,43911,29412,82214,45115,328
Total Assets9,04710,35015,10417,78323,23123,47723,76527,64225,56228,83436,68950,673
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from Operating Activity9941,8941,3129191,2822,5053,2932,1042,6893,2286,7812,117
Cash from Investing Activity-465-860-2,872-974-3,977-1,012-8351,1371,178-1,492-8,363-7,895
Cash from Financing Activity-351-9352,316521,885-1,094-2,549-868-4,400-1,8101,9955,807
Net Cash Flow17899756-3-811399-902,373-534-7541428
Free Cash Flow498936-1,623-1162361,6172,4461,0501,6972,3455,139-530
CFO/OP79%109%81%54%65%100%109%83%85%84%122%44%
Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days6768899811094768094976473
Inventory Days175158193211208207227245197202227282
Days Payable125154165167149151155141123125131142
Cash Conversion Cycle11871116142169150148184168175160212
Working Capital Days6-1-341710-19-61970883-40
ROCE %23%28%16%18%15%11%14%13%15%22%24%21%
Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters74.98%74.98%74.98%74.98%74.98%74.98%75.00%75.00%75.00%75.00%75.00%75.02%
FIIs4.85%4.99%5.72%5.59%7.52%7.53%7.31%7.13%7.34%7.06%6.95%6.89%
DIIs13.01%12.96%12.55%12.56%10.59%10.61%10.95%11.09%10.86%11.08%11.20%11.27%
Government0.07%0.07%0.07%0.07%0.05%0.05%0.05%0.04%0.00%0.00%0.00%0.00%
Public7.07%6.99%6.66%6.81%6.85%6.85%6.69%6.74%6.81%6.86%6.86%6.83%
No. of Shareholders2,97,9533,06,4952,94,3243,36,3093,70,8633,65,3563,71,6193,86,1273,96,1054,03,2664,18,3143,99,251

Fundamentals

Market Cap₹ 1,19,750 Cr.
Current Price₹ 1,200
Stock P/E24.6
Book Value₹ 269
ROCE21.1 %
ROE21.2 %
Dividend Yield0.08 %
Face Value₹ 1.00
Compounded Sales Growth (TTM)21%
Compounded Profit Growth (TTM)5%
Consolidated figures.
Valuation
Market capRs 115,284 Cr
Enterprise valueRs 126,364 Cr
P/E (TTM)25.54x
Price to book4.25x
Price to sales4.03x
EV / EBITDA15.33x
EV / EBIT19.39x
EV / sales4.42x
Price to cash flow54.47x
Earnings yield3.91%
Dividend yield0.09%
P/E, 3-year average21.12x
P/B, 3-year average4.02x
P/E, 5-year average19.34x
P/B, 5-year average3.40x
Profitability
Operating margin (excl. other income)31.22%
Operating margin (incl. other income)31.19%
EBITDA margin28.83%
Pre-tax margin21.01%
Net profit margin15.78%
Net margin, latest quarter11.72%
ROE19.74%
ROCE21.15%
ROA11.54%
ROE, 3-year average20.36%
ROCE, 3-year average24.01%
ROA, 3-year average13.18%
ROE, 5-year average20.47%
ROCE, 5-year average22.50%
ROA, 5-year average12.87%
ROIC (approx.)12.96%
Tax rate24.09%
Other income / net worth-0.03%
Growth
Sales growth (latest year)16.81%
Profit growth (latest year)11.37%
Sales CAGR, 3 years16.35%
Sales CAGR, 5 years12.45%
Profit CAGR, 3 years36.99%
Profit CAGR, 5 years18.76%
Sales growth QoQ5.67%
Profit growth QoQ-26.15%
Sales growth YoY (latest quarter)21.96%
Profit growth YoY (latest quarter)-35.93%
Per share
EPS (TTM)Rs 44.85
EPS (latest year)Rs 50.09
EPS (latest quarter)Rs 9.34
EPS, 3-year averageRs 44.47
EPS, 5-year averageRs 39.32
Book value per shareRs 269.43
Sales per shareRs 284.15
Cash flow per shareRs 21.03
Free cash flow per shareRs -5.27
Dividend per share (latest year)Rs 1.00
Dividend per share, 3-year averageRs 5.00
Dividend per share, 5-year averageRs 4.70
Dividends
Dividend payout2.00%
Dividend payout, 3-year average11.42%
Dividend payout, 5-year average14.19%
Efficiency
Asset turnover0.54x
Fixed asset turnover1.13x
Inventory turnover1.50x
Inventory days244 days
Debtor days73 days
Debtors turnover5.01x
Creditor days142 days
Cash conversion cycle212 days
Working capital days-40 days
Leverage
Total debtRs 12,496 Cr
Cash and bankRs 1,417 Cr
Net debtRs 11,079 Cr
Debt to equity0.46x
Net debt / EBITDA1.34x
Interest coverage12.77x
Current ratio (filing 2026-03-31)1.27x
Quick ratio (filing 2026-03-31)0.91x
Trade payables (filing 2026-03-31)Rs 2,845 Cr
Owners' fund to total sources53.50%
Debt to assets24.66%
Cash flow
Cash from Operating Activity (latest year)Rs 2,117 Cr
Cash from Investing Activity (latest year)Rs -7,895 Cr
Cash from Financing Activity (latest year)Rs 5,807 Cr
Net Cash Flow (latest year)Rs 28 Cr
Free cash flow (latest year)Rs -530 Cr
FCFE (approx.: FCF + change in debt)Rs 8,753 Cr
Cash from ops / profit, 5 years0.83x
Sales to cash flow12.83x
Statement figures
Net sales (TTM)Rs 28,592 Cr
Net sales (latest year)Rs 27,148 Cr
Sales (latest quarter)Rs 8,017 Cr
Operating profit excl. other income (latest year)Rs 8,475 Cr
Operating profit (latest quarter)Rs 1,929 Cr
Other income (TTM)Rs -74 Cr
EBITDA (TTM)Rs 8,242 Cr
PBDT (TTM)Rs 7,732 Cr
Profit before tax (TTM)Rs 6,007 Cr
Tax (latest year)Rs 1,595 Cr
Net profit (TTM)Rs 4,513 Cr
Net profit (latest year)Rs 5,040 Cr
Net profit (latest quarter)Rs 940 Cr
Depreciation (TTM)Rs 1,725 Cr
Depreciation (latest quarter)Rs 555 Cr
Interest (TTM)Rs 510 Cr
Cost of goods sold (latest year)Rs 8,421 Cr
Total expenditure (latest year)Rs 18,673 Cr
Total income (latest year)Rs 27,141 Cr
Share capitalRs 101 Cr
ReservesRs 27,011 Cr
Shareholders' fundsRs 27,111 Cr
Total assetsRs 50,673 Cr
Net blockRs 24,106 Cr
Capital work in progressRs 3,698 Cr
InvestmentsRs 7,540 Cr
ReceivablesRs 5,416 Cr
InventoryRs 5,628 Cr
Other liabilitiesRs 11,065 Cr
Shares outstanding (crore)100.62
Ownership
Promoter holding75.02% (+0.02 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
P/E 25.5 is at the 58th percentile of its own 9.4-year range (median 22.0, low 7.8, high 52.9).
P/B 4.25 is at the 58th percentile (median 4.07).
Monthly. Market cap from split-adjusted price; profit and book value as reported by that month. A low percentile means cheap versus its own history, not cheap versus peers.
PeriodZYDUSLIFENifty 50Difference
1 week-2.9%-2.8% -0.2 pts
1 month-1.9%-6.8% +4.9 pts
3 months+0.4%-7.6% +8.1 pts
6 months+31.5%+0.4% +31.1 pts
1 year+12.4%-9.9% +22.3 pts
2 years+8.6%-13.6% +22.1 pts
3 years+86.3%+14.2% +72.1 pts
5 years+106.2%+27.9% +78.3 pts
169 mutual fund schemes hold about ₹8,125 Cr. Over three months 45 bought more and 34 sold (share counts, price move removed).
FundWeightEst. Cr3m shares
Parag Parikh Flexi Cap Fund1.52%2,237 +1%
Kotak Flexi Cap Fund2.14%1,209 +3%
Kotak Flexi Cap Fund2.14%1,203 +3%
HSBC Midcap Fund1.98%341 +100%
ICICI Pru Large Cap Fund0.36%288 -9%
Quant Mid Cap Fund2.98%240 +100%
Bandhan Large & Mid Cap Fund1.12%235 +79%
Quant Flexi Cap Fund2.74%202 +100%
Quant Multi Cap Fund2.60%201 +100%
ICICI Pru Nifty Next 50 Index Fund1.14%116 +0%
Kotak Arbitrage Fund(M0.15%112 -24%
Quant ELSS Tax Saver Fund0.77%104 +100%
Quant Large Cap Fund2.79%100 +100%
Parag Parikh ELSS Tax Saver Fund1.68%94 +4%
Quant Large & Mid Cap Fund2.62%92 +100%
UTI Nifty Next 50 Index Fund1.14%86 +0%
Quant Aggressive Hybrid Fund3.63%78 +100%
Quant Quantamental Fund4.28%70 +100%
Quant Multi Asset Allocation Fund1.00%65 +100%
HDFC Pharma and Healthcare Fund1.93%64 -18%
LIC MF Large & Midcap Fund1.58%51 +1%
HDFC Large & Mid Cap Fund0.13%40 +0%
Quant Healthcare Fund9.30%40 +100%
ICICI Pru Arbitrage Fund0.11%38 -69%
Aditya Birla SL Quant Fund1.83%37 +100%

Red flags

F-score 4 of 8
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.

Insider trades

NSE insider and takeover-code disclosures
DateWhoRoleSideSharesValueHow
2025-11-12Jasodaben Babubhai PatelPromoter Groupbuy1,000Rs 0.10 CrMarket Purchase
2024-03-28ZYDUS FAMILY TRUSTPromoterssell10,000Rs 1.01 CrMarket Sale
2024-03-28ZYDUS FAMILY TRUSTPromoterssell30,000Rs 3.03 CrMarket Sale
2024-03-28DEVAL DHIRAJBHAI SHAHImmediate relativesell292Rs 0.03 CrMarket Sale
2024-03-28DEVAL DHIRAJBHAI SHAHImmediate relativeother292Rs 0.03 CrRevokation of Pledge
2024-03-27ZYDUS FAMILY TRUSTPromoterssell565,466Rs 57.04 CrMarket Sale
2024-03-27ZYDUS FAMILY TRUSTPromoterssell17,534Rs 1.78 CrMarket Sale
2024-03-26HARSHA JYOTINDRA GORImmediate relativesell1,000Rs 0.10 CrMarket Sale
2024-03-26DEVAL DHIRAJBHAI SHAHImmediate relativeother150Rs 0.02 CrRevokation of Pledge
2024-03-26DEVAL DHIRAJBHAI SHAHImmediate relativesell150Rs 0.02 CrMarket Sale
2024-03-22DEVAL DHIRAJBHAI SHAHImmediate relativeother500Rs 0.05 CrRevokation of Pledge
2024-03-22DEVAL DHIRAJBHAI SHAHImmediate relativesell500Rs 0.05 CrMarket Sale
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.

Latest quarter

Jun 2026
Sales ₹8,017 Cr +22.0% vs Jun 2025. Net profit ₹990 Cr -34.9%.

Activity

Compare
CompanyMcap (Cr)P/EROCE
Sun Pharmaceutical Industries Ltd447,47635.420.5 %
Divis Laboratories Ltd250,36384.022.0 %
Torrent Pharmaceuticals Ltd186,15283.415.2 %
Cipla Ltd111,43031.115.5 %
Laurus Labs Ltd106,92897.817.8 %
Mankind Pharma Ltd105,12049.313.5 %
Dr Reddys Laboratories Ltd104,49432.413.0 %
Aurobindo Pharma Ltd97,68225.812.9 %
Lupin Ltd93,84015.829.9 %
Glenmark Pharmaceuticals Ltd68,90522.139.8 %
Alkem Laboratories Ltd62,77227.621.2 %
Biocon Ltd61,43984.53.61 %
Abbott India Ltd57,94935.944.8 %
Gland Pharma Ltd49,33343.115.1 %
Ipca Laboratories Ltd49,17035.817.0 %
No bulk or block deals on record.
Ex-dateActionFactor
2026-07-24Dividend - Re 1 Per Share
2026-05-29Buy Back
2025-07-25Dividend - Rs 11 Per Share
2024-07-26Dividend - Rs 3 Per Share
2024-02-23Buy Back
2023-07-28Dividend - Rs 6 Per Share
2022-07-28Dividend - Rs 2.50 Per Share
2022-06-01Buyback
2021-07-28 Annual General Meeting/Dividend - Rs 3.50 Per Share
2020-08-12 Annual General Meeting
2020-03-23 Interim Dividend - Rs 3.50 Per Share
2019-07-25 Annual General Meeting/Dividend - Rs 3.50 Per Share
2018-07-31 Annual General Meeting/Dividend- Rs 3.50 Per Share (Purpose Revised)
2017-07-27 Annual General Meeting
2017-03-16 Interim Dividend Rs 3.20 Per Share (Purpose Revised)
2016-07-21 Annual General Meeting
2016-03-17 Interim Dividend - Rs 3.20/- Per Share
2015-10-06 Face Value Split (Sub-Division) - From Rs 5/- Per Share To Re 1/- Per Share0.2000
2015-07-30Annual General Meeting/Dividend - Rs 12/- Per Share
2014-07-17Annual General Meeting / Dividend - Rs 9/- Per Share
2013-09-19Annual General Meeting
2013-06-11Interim Dividend Rs 7.50/- Per Equity Share
2012-07-26Annual General Meeting/Dividend Rs 7.50 Per Share
2011-07-07Annual General Meeting And Dividend Rs.6.25 Per Share
2010-07-15Dividend-Rs.5/- Per Share
2010-04-05Bonus 1: 20.6667
2009-07-16Agm/Div-Rs.4.50 Per Share
2008-12-29Scheme Of Arrangement
2008-07-10Agm/Dividend - 90%
2007-07-12Agm/Div-Rs.4/- Per Sh
2006-08-30Bonus 1:10.5000
2006-07-13Dividend-120%
DateTypeWhat it says
2026-10-01General UpdatesGeneral Updates
2026-09-28Press ReleaseA press release dated September 28, 2026, titled "USFDA inspection concludes at Zydus manufacturing plant at SEZ II, Ahmedabad".
2026-09-26Press ReleaseA press release dated September 26, 2026, titled "USFDA inspection of pharmacovigilance and post marketing system concludes at Zydus USA Office with ...
2026-09-11Credit RatingCredit Rating
2026-09-11Concall / analyst meetSchedule of meet
2026-09-05General UpdatesGeneral Updates
2026-09-01General UpdatesGeneral Updates
2026-08-31Press ReleaseA press release dated August 31, 2026, titled "Zydus Announces Positive Topline Results from Completed EVIDENCES-X Phase II(b) Clinical Trial of Sarog...
2026-08-26General UpdatesGeneral Updates
2026-08-25General UpdatesGeneral Updates
2026-08-24UpdatesDisclosure under SEBI (Prohibition of Insider Trading) Regulations, 2015.
2026-08-23Investor PresentationInvestor Presentation
2026-08-21General UpdatesGeneral Updates
2026-08-21Press ReleaseA press release dated August 21, 2026, titled "Zydus announces final approval from the USFDA for Ascorbic Acid Injection with 180-Days CGT exclusivity...
2026-08-18Concall / analyst meetTranscript
2026-08-17Concall / analyst meetSchedule of meet
2026-08-12Concall / analyst meetSchedule of meet
2026-08-11Director changeChange in Director(s) of the company.
2026-08-11Shareholder meetingProceedings of Annual General Meeting held on August 11, 2026. Further, the company has submitted the Exchange a copy of Scrutinizers report along wit...
2026-08-11Concall / analyst meetLink of Recording
2026-08-11UpdatesReporting of violation of Code of Conduct under SEBI (Prohibition of Insider Trading) Regulations, 2015.
2026-08-11Press ReleaseA press release dated August 11, 2026, titled "Sentynl Therapeutics and Mereo BioPharma Announce Option and License Agreement for alvelestat in Alpha-...
2026-08-11Press ReleaseA press release dated August 11, 2026, titled "Press Release".
2026-08-11Investor PresentationInvestor Presentation
2026-08-11Board meeting outcomeZydus Lifesciences Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
Put / call open interest0.57
Max pain (expiry 2026-10-27)1,190
Largest call open interest at1,200
Largest put open interest at1,200
Implied volatility, at the money27.7%
Underlying at snapshot1,145.70
Open interest by strike around the price, nearest expiry. End-of-day NSE snapshot, 01-Oct-2026 15:40:00. Max pain is the strike where option buyers together would lose the most at expiry.
Trade dateShares sold short
2026-09-3021
2026-09-2926,215
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Order dateForumCase
2021-07-20NCLTSatya Saxena Vs Cadila Healthcare Ltd & Ors
2021-06-22NCLTSatya Saxena Vs Cadila Healthcare Ltd & Ors
2021-04-20NCLTSatya Saxena Vs Cadila Healthcare Ltd & Ors
2021-04-05NCLTCadila Healthcare Ltd. Managerial Cadre Employees Provident Fund Vs Punjab State Industrial Development Corporation Ltd.
2021-03-08NCLTSatya Saxena Vs Cadila Healthcare Ltd & Ors
2021-01-18NCLTSatya Saxena Vs Cadila Healthcare Ltd & Ors
Orders from NCLT, NCLAT and CESTAT naming the company. Click a row for the order.
Not on any NSE surveillance list in the latest file.

Quick answers

What is the market cap of Zydus Lifesciences Ltd?

Zydus Lifesciences Ltd (ZYDUSLIFE) has a market capitalisation of Rs 1,19,750 Cr. at the 2026-10-01 close.

What is the P/E ratio of Zydus Lifesciences Ltd?

Zydus Lifesciences Ltd trades at a P/E of 24.6 on trailing twelve-month profit, at the 2026-10-01 close.

What were Zydus Lifesciences Ltd's latest quarterly results?

In the Jun 2026 quarter, Zydus Lifesciences Ltd sales was Rs 8,017 Cr (+22.0% vs Jun 2025) and net profit was Rs 990 Cr.

What is the 52-week high and low of Zydus Lifesciences Ltd?

The 52-week high is Rs 1,232.10 and the 52-week low is Rs 835.50.

Data: NSE and BSE daily reports, company filings. Numbers only, not investment advice, not a SEBI-registered research service.AboutMethodologyFAQResearchContactTermsPrivacyDisclaimerUpdated 2026-10-03